A primer on recurrent and de novo glomerulonephritis in renal allografts

Yakupoglu U et al. (2004) Post-transplant nephrotic syndrome: a comprehensive clinicopathologic study. Kidney Int 65: 2360–2370

Chung J et al. (2000) Glomerulonephritis is the major cause of proteinuria in renal transplant recipients: histopathologic findings of renal allografts with proteinuria. Clin Transplant 14: 499–504

Suzuki H et al. (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63: 2286–2294

Moriyama T et al. (2005) Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation. Clin Transplant 19 (Suppl 14): S41–S48

Schwartzman MS et al. (2005) Transplantation and 6-month follow-up of renal transplantation from a donor with systemic lupus erythematosus and lupus nephritis. Am J Transplant 5: 1772–1776

Briggs JD and Jones E (1999) Recurrence of glomerulonephritis following renal transplantation. Nephrol Dial Transplant 14: 564–565

Chadban S (2001) Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 12: 394–402

Hariharan S et al. (1998) Recurrent and de novo renal diseases after renal transplantation: a report from the Renal Allograft Disease Registry. Am J Kidney Dis 31: 928–931

Hariharan S et al. (1999) Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 68: 635–641

Briganti EM et al. (2002) Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347: 103–109

Nankivell BJ et al. (2004) Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 78: 461–468

Ibrahim H et al. (2006) Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol. Transplantation 81: 214–219

Morozumi K et al. (2004) Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? Transplant Proc 36 (Suppl 2): 251S–256S

Cosio FG et al. (1999) Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival. Am J Kidney Dis 34: 731–738

Zimmerman S (1984) Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 22: 32–38

Sharma M et al. (2002) Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 73: 366–372

Musante L et al. (2002) Characterization of plasma factors that alter the permeability to albumin within isolated glomeruli. Proteomics 2: 197–205

Coward RJ et al. (2005) Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, podocin, and CD2 associated protein in cultured human podocytes. J Am Soc Nephrol 16: 629–637

Caridi G et al. (2003) Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 14: 1278–1286

Caridi G et al. (2003) Podocin mutations in sporadic focal-segmental glomerulosclerosis occurring in adulthood. Kidney Int 64: 365

Ruf R et al. (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15: 722–732

Weber S et al. (2004) NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 66: 571–579

Carraro M et al. (2002) Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13: 1946–1952

Newstead CG (2003) Recurrent disease in renal transplants. Nephrol Dial Transplant 18 (Suppl 6): Svi68–Svi74

Swaminathan S et al. (2006) Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 21: 2607–2614

Adrogue HE et al. (2007) Coincident activation of Th2 T cells with onset of the disease and differential expression of GRO-gamma in peripheral blood leukocytes in minimal change disease. Am J Nephrol 27: 253–261

Zafarmand A et al. (2002) De novo minimal change disease associated with reversible post-transplant nephrotic syndrome: a report of five cases and review of literature. Clin Transplant 16: 350–361

Ronco P and Debiec H (2005) Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol 16: 1205–1213

Cosyns JP et al. (1998) Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors. Clin Nephrol 50: 144–153

Requiao-Moura R et al. (2007) Prognostic factors associated with poor graft outcomes in renal recipients with post-transplant glomerulonephritis. Clin Transplant 21: 363–370

Schwarz A et al. (1994) Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation. Transplantation 58: 650–654

Poduval RD et al. (2003) Treatment of de novo and recurrent membranous nephropathy in renal transplant recipients. Semin Nephrol 23: 392–399

Joosten SA et al. (2005) Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 5: 383–393

Berger SP and Daha MR (2007) Complement in glomerular injury. Semin Immunopathol 29: 375–384

Braun MC et al. (2005) Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: the North American Pediatric Renal Transplant Cooperative Study Experience. J. Am Soc Nephrol 16: 2225–2233

Little MA et al. (2006) Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 69: 504–511

Levy J et al. (2001) Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134: 1033–1042

Khandelwal M et al. (2004) Recurrence of anti-GBM disease 8 years after renal transplantation. Nephrol Dial Transplant 19: 491–494

Borza DB et al. (2005) Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am J Kidney Dis 45: 397–406

Nachman PH et al. (1999) Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 56: 1544–1550

Elmedhem A et al. (2003) Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 18: 1001–1004

Choy BY et al. (2006) Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 6: 2535–2542

Gera M et al. (2007) Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int 71: 1296–1301

Barratt J et al. (2007) Immunopathogenesis of IgAN. Semin Immunopathol 29: 427–443

Gough J et al. (2005) Recurrent and de novo glomerular immune-complex deposits in renal transplant biopsies. Arch Pathol Lab Med 129: 231–233

Bumgardner GL et al. (1998) Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation 65: 1053–1060

Jeong HJ et al. (2004) IgA nephropathy in renal allografts—recurrence and graft dysfunction. Yonsei Med J 45: 1043–1048

Chacko B et al. (2007) Outcomes of renal transplantation in patients with immunoglobulin A nephropathy in India. J Postgrad Med 53: 92–95

Choy BY et al. (2003) Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant 18: 2399–2404

Andresdottir MB et al. (2001) Favorable outcome of renal transplantation in patients with IgA nephropathy. Clin Nephrol 56: 279–288

Wang AY et al. (2001) Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis 38: 588–596

McDonald S et al. (2006) Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation 82: 759–762

Jeong HJ et al. (2004) Glomerular crescents are responsible for chronic graft dysfunction in post-transplant IgA nephropathy. Pathol Int 54: 837–842

Coppo R et al. (2007) Serological and genetic factors in early recurrence of IgA nephropathy after renal transplantation. Clin Transplant 21: 728–737

Kashtan CE (2006) Renal transplantation in patients with Alport syndrome. Pediatr Transplant 10: 651–657

Jais JP et al. (2003) X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol 14: 2603–2610

Artz MA et al. (2003) Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 76: 821–826

Caprioli J et al. (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment and outcome. Blood 108: 1267–1279

Ponticelli C and Banfi G (2006) Thrombotic microangiopathy after kidney transplantation. Transpl Int 19: 789–794

Sellier-Leclerc A et al. (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18: 2392–2400

Bresin E et al. (2006) Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 1: 88–99

Reynolds JC et al. (2003) Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 42: 1058–1068

Karthikeyan V et al. (2003) Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 3: 1289–1294

Zarifian A et al. (1999) Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 55: 2457–2466

Schwimmer J et al. (2003) De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 41: 471–479

Opelz G et al. (2006) No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 17: 3257–3262

Weber S and Tönshoff B (2005) Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation 80 (Suppl): S128–S134

Vincenti F and Ghiggeri GM (2005) New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 5: 1179–1185

Yabu JM et al. (2008) Rituximab failed to improve nephrotic syndrome in renal transplant recipients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8: 222–227

Fine RN (2007) Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 22: 496–502

Ruggenenti P et al. (2006) Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 1: 738–748

Gallon L and Chhabra D (2006) Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 6: 3017–3021

Geetha D et al. (2007) Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases. Am J Transplant 7: 2821–2825

Courtney AE et al. (2006) Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transplant 21: 3550–3554

Meier-Kriesche HU et al. (2003) Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75: 1291–1295

Fernández-Fresnedo G et al. (2004) Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 19 (Suppl 3): Siii47–Siii51

Magee C and Pascual M (2004) Update in renal transplantation. Arch Intern Med 164: 1373–1388

Matas AJ (2006) Recurrent disease after kidney transplantation—it is time to unite to address this problem! Am J Transplant 6: 2527–2528

Floege J (2003) Recurrent glomerulonephritis following renal transplantation: an update. Nephrol. Dial Transplant 18: 1260–1265

Noris M and Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16: 1035–1050